BRD2 upregulation as a pan-cancer adaptive resistance mechanism to BET inhibition
{{output}}
Bromodomain and extraterminal motif (BET) inhibitors, such as JQ1, are promising cancer therapeutics that target epigenetic regulators, particularly BRD4. However, resistance to BET inhibitors (BETi) limits their clinical utility, necessitating a better unders... ...
